A longstanding executive for a foundational publicly traded Canadian cannabis firm is set to return to the space as CEO of a company looking to shift strategies.

Terry Booth is expected to become the official new leading executive at Australis Capital (CSE:AUSA,OTCQB:AUSAF) pending an acquisition deal set to close before February 22.


As founder and CEO, he led Aurora Cannabis (NYSE:ACB,TSX:ACB) through the initial green rush cycle of hype and growth for Canadian cannabis names, and then through various downturns caused by poor financial results in the overall industry and difficulties with the Canadian legal marketplace rollout.

Booth was dismissed from his leadership position at Aurora Cannabis in February 2020. While he remained on its board of directors, he proceeded to leave that role four months after.

The conclusion of his time at Aurora represented a change in the landscape of leading executives for Canadian cannabis companies. But Booth never saw it as the end of his time in the industry. “I probably didn’t really leave the cannabis space, I think I was retired for about six hours,” he said.

Now Booth is expected to become CEO of Australis after joining an investor group that challenged the executives formerly in charge of the company in an all-out public battle.

The executive opened up to the Investing News Network (INN) about his time away, lessons learned from the downgrade in cannabis investing and exactly where he wants to see Australis in the future.

Where does Booth want Australis to go in the future?

What exactly can investors expect of a new Booth-led cannabis company? Nothing resembling Aurora, he said. The future for Australis will have a different business path and potentially a name change.

What Booth wants the company to become is a US cannabis player that is involved in the buildout of facilities for other operators; he also wants Australis to have deals in place that will allow it to secure cannabis from these operators.

“We’re not building an Aurora 2.0 —  we’re not going to build a bunch of big facilities and then cultivate cannabis,” he explained to INN. “But we are going to build big facilities for others and have them cultivate a certain amount of cannabis assigned to us — that would be 5 percent or 10 percent depending upon the size of that facility.”

Building expertise will come from greenhouse facility design and consulting firm Aurora Larssen Projects, otherwise known as ALPS, which Booth said he joined last year after Aurora divested its stake in the firm.

Australis is currently in the process of absorbing ALPS, a transaction that will confirm Booth’s appointment as leading executive. Additionally, the firm is purchasing Green Therapeutics, a Nevada-based company producing branded cannabis products.

The former Aurora CEO told INN he has been able to look back on shortcomings during his time at the helm of the cannabis producer — pitfalls he doesn’t want to repeat now with Australis.

One of Booth’s biggest reflections is that acquisitions of distressed assets shouldn’t be forced just because an idea sounds good on paper. This concept, he said, will be a guiding principle for the future strategy at Australis. According to the executive, any acquisitions or deals the company makes will be dictated by positive cash flow or positive EBITDA results.

“I want to stay away from being too diluted,” Booth said of his desire to prevent Australis from needing to rush and get money at a low cost from the market, as was the case with Aurora at times.

What’s the backstory between Australis and Aurora?

Booth’s return as Australis CEO is mirrored by his return of sorts to the Aurora corporate family.

Australis is a cannabis company originally launched in 2018 by Aurora as a spin off designed to explore the market for investing opportunities in various geographies, including the US market.

The two companies have kept a distance since Aurora’s stance with securities regulators cannot be compromised by way of doing direct business in the federally illegal US cannabis market.

“We were supposed to be their big brother, yet it didn’t really occur that way,” Booth told INN.

He said after Australis completed a previous deal in Nevada, Aurora was set to help with the buildout of a facility space up until Aurora’s advisors shut down the notion of participating in the US marketplace in any capacity. “We (could) only be an advisor to Australis, and we weren’t really tapped on the shoulder very much,” Booth said.

The downturn in operations led to what Booth called mistakes for Australis. The company began exploring fintech business opportunities in 2020, when a group of investors banded together to challenge its management team.

After weeks of escalation, Australis saw its future change when the board nominees propped up by the company’s previous management bowed out. This led to a victory for the dissident group known as the Concerned Shareholders of Australis Capital, which had support from Booth.

Can Australis strike up a business relationship with Aurora?

Despite the distance between Aurora and Australis, the two companies are still linked by way of a set of warrants held by Aurora, which won’t expire until September 2028.

In its most recent quarterly report, Aurora restated its current position in regards to Australis. Company documents show Aurora still holds 22.6 million warrants exercisable at a price of $0.20 per share; in total, these warrants equate to around a 20 percent stake in Australis.

The Canadian producer also reaffirmed it cannot act on these warrants until US federal law permits all of Australis’ business operations, or until Aurora receives permission to act on them from securities regulators. The latter would likely not happen without federal legalization.

But where exactly does that leave the current business relationship, if any at all, between the two corporations? Booth told INN he wants there to be one and said he is looking forward to potential discussions with Aurora.

“Some people may see that warrant thing as a hangover, but I intend to nurture the relationship with Aurora,” Booth said.

The executive reiterated that for any action to take place with the warrants, cannabis will have to be deemed legal in the US. But in the future, if there is a change in policy in the US market and the warrants came into play, he wouldn’t turn down the opportunity to work with Aurora.

“A lot of factors would say that they wouldn’t do it. And a lot of reasons that I wouldn’t be bothered if they did,” Booth said. “If you know me, you know I’ll look at any deal. You know I don’t harbor resentment (toward) anybody. Sure, there’s some people that pissed me off at Aurora, they still do, but most of them have left after I left. I don’t expect that would impede me or them from doing business together.”

Don’t forget to follow us @INN_Cannabis for real-time updates!

Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

Editorial Disclosure: The Investing News Network does not guarantee the accuracy or thoroughness of the information reported in the interviews it conducts. The opinions expressed in these interviews do not reflect the opinions of the Investing News Network and do not constitute investment advice. All readers are encouraged to perform their own due diligence.

CanBud Distribution Corporation (CSE: CBDX) (FSE: CD0) (“CanBud” or the “Corporation”) is pleased to announce that it has closed the final tranche of its oversubscribed non-brokered private placement for aggregate gross proceeds of approximately $4,730,000 (the “Offering”).

The Corporation issued a combined total of 39,409,346 units (each a “Unit“) at price of $0.12 per Unit, with each Unit comprised of one common share in the capital of the Corporation (each a “Common Share“) and one common share purchase warrant (each a “Warrant“). Each Warrant entitles the holder to purchase one additional Common Share at an exercise price of $0.22 within 24 months of the closing of the Offering (the “Warrant Term“), provided, however that if the closing price of the Common Shares on the Canadian Securities Exchange (the “CSE“) (or any such other stock exchange in Canada as the Common Shares may trade at the applicable time) is $0.25 or greater per Common Share for a period of five (5) consecutive trading days at any time after the closing date of the Offering, the Corporation may accelerate the Warrant Term such that the Warrants shall expire on the date which is 30 days following the date a press release is issued by the Corporation announcing the reduced warrant terms.

Keep reading... Show less

Thoughtful Brands Inc. (CSE:TBI)(FSE:1WZ1)(OTCQB:PEMTF) (the “Company” or “Thoughtful Brands) announces that the letter of intent with Franchise Cannabis Corp. (“FCC”), previously announced in January, has been terminated. The previously announced European joint venture with FCC will continue and allow the Company to launch and tailor its products to European consumer demands

In connection with termination of the merger transaction with FCC, the Company has agreed to pay FCC $100,000 in cash and to issue FCC 5,000,000 common shares of the Company at a deemed value of $0.05 per share. The common shares will be subject to a four-month-and-one-day statutory hold period in accordance with applicable securities laws.

Keep reading... Show less

Mergers and acquisitions (M&A) in cannabis space have helped boost the industry to new levels.

Keep reading... Show less

Strategic sale of non-core assets by Lobe adds non-dilutive capital and shareholder value

Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) (“Lobe” or the “Company”) is pleased to announce, further to its press release dated February 23, 2021, that it has completed the sale to Ionic Brands Corp. (“Ionic Brands”) of Lobe’s non-core cannabis assets relating to Washington-based Cowlitz County Cannabis Cultivation Inc. (“Cowlitz”) held by Lobe’s subsidiary vendor, Green Star Biosciences Inc. (the “Transaction”).

Keep reading... Show less

Adding to its existing presence on the west coast of the United States, all five KOIOS™ flavours and all four Fit Soda™ flavours will be carried in Metropolitan Market stores beginning on Monday, March 22, 2021. Serving the Seattle-Tacoma area (population 3.87 million), Metropolitan Market is one of five chains under its parent firm Good Food Holdings, which has a total of 51 stores in California, Oregon, and Washington State.

Koios Beverage Corp. (CSE: KBEV; OTC: KBEVF) (the “Company” or “Koios”) is pleased to announce that beginning on Monday, March 22, 2021, Koios’ entire line of canned beverage products will be sold at all locations of Metropolitan Market, an urban format supermarket chain in the Seattle-Tacoma area of Washington State. In Q1 2021, the Company announced multiple placements of its beverage products with regional grocers in markets on the west coast of the United States including Market of Choice in Oregon Jensen’s in Southern California and major natural grocery chain Sprouts Farmers Market which has a substantial west coast presence with over one third of its locations (360+ stores across 23 states) in California as well as Washington State 1 . The Company has also recently announced other developments relating to its expansion efforts being undertaken in 2021 such as an in-house beverage canning facility and distribution agreements with regional and national wholesale partners.

Keep reading... Show less